Back to top
more

BioCryst Pharmaceuticals (BCRX)

(Real Time Quote from BATS)

$8.11 USD

8.11
504,993

+0.33 (4.24%)

Updated Nov 11, 2024 12:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of -100% and 6.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for BioCryst (BCRX)

by Zacks Equity Research

BioCryst (BCRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Earnings Preview: Ionis Pharmaceuticals (IONS) Q4 Earnings Expected to Decline

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -23.48% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Predict a 48% Upside in BioCryst (BCRX): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for BioCryst (BCRX) points to a 47.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

BioCryst (BCRX) Down as it Discontinues Developing PNH Drug

by Zacks Equity Research

BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of 28.13% and 3.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Has Alignment Healthcare (ALHC) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Alignment Healthcare (ALHC) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.

BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of 11.11% and 2.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength?

by Zacks Equity Research

BioCryst (BCRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of -2.56% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q1 Earnings Expected to Decline

by Zacks Equity Research

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in BioCryst (BCRX): Can Its 15.2% Jump Turn into More Strength?

by Zacks Equity Research

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

BioCryst (BCRX) Pauses Enrolment in Key Studies, Stock Down

by Zacks Equity Research

BCX9930 is a BioCryst Pharmaceuticals' (BCRX) oral Factor D inhibitor being evaluated in several studies for the treatment of complement-mediated diseases

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of -29.03% and 2.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of 7.14% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

BioCryst (BCRX) Stock Up on Q4 Orladeyo Preliminary Sales

by Zacks Equity Research

BioCryst's (BCRX) sole marketable drug, Orladeyo reports preliminary sales for the fourth quarter. The company also provides its revenue guidance for 2022.

BioCryst (BCRX) Moves 27.9% Higher: Will This Strength Last?

by Zacks Equity Research

BioCryst (BCRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

BioCryst (BCRX) Begins Enrollment in PNH Study on BCX9930

by Zacks Equity Research

BioCryst (BCRX) starts patient enrollment in the pivotal REDEEM-2 study evaluating BCX9930 for treating patients with paroxysmal nocturnal hemoglobinuria.